Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3

Summary

This will be a single centre, Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of APB-R3 in Healthy Participants.

Timeline

Start

2023-03-08

Primary completion

2023-12-19

Completion

2023-12-19

Outcome

Met primary endpoint

release “APB-R3의 1차지표인 안전성과 내약성에 문제가 없음을 확인했다.” aprilbio.com ↗

Drugs

Indications